Author:
Stewart Ian E.,Durham Phillip G.,Sittenauer Jacob M.,Barreda Aranza P.,Stowell Grayson W.,Moody Carmella,Mecham Jeffery B.,Simpson Catherine,Daily Sharon,Maloney Sara E.,Williams Mark D.,Severynse-Stevens Diana,Hickey Anthony J.
Funder
National Institute for Allergy and Infectious Disease
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference20 articles.
1. World Health Organization. https://cdn.who.int/media/docs/default-source/hq-tuberculosis/impact-of-the-covid-19-pandemic-on-tb-detection-and-mortality-in-2020.pdf?sfvrsn=3fdd251c_16&download=true. 2021.
2. Zimmer A, Klinton J, Oga-Orenka C, Heitkamp P, Nyirenda C, Furin J, Pai M. Tuberculosis in times of COVID-19. J Epidemiol Community Health 2021;EPub ahead of Print 17 Sept 2021:https://doi.org/10.1136/jech-2021-217529.
3. Kant S, Tyagi R. The impact of COVID-19 on tuberculosis: challenges and opportunities. Ther Adv Infectious Dis. 2021;8:1–7.
4. World Health Organization. WHO consolidated guidelines on drug resistant tuberculosis treatment. In. Geneva, Switzerland: World Health Organization; 2019. p. ISBN 978–992–974-15505-15509.
5. Conradie F, Diacon A, Ngubane N, Howell P, Everitt D, Crook A, Mendel C, Egizi E, Moreira J, Timm J, McHugh T, Wills G, Bateson A, Hunt R, VanNiekerk C, Li M, Olugbosi M, Spigelman M. Badaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non responsive multidrug resistant pulmonary tuberculosis. N Engl J Med. 2020;382:893–902.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献